A double-blind, randomized, 2-way cross-over, phase II, efficacy trial in cancer patients to assess the overall efficacy, patient preference, morphine related side effect profile and safety of the Egalet controlled release morphine formulation 30-240 mg once daily compared to MST Continus [morphine sulphate] 15-120 mg twice daily after 2 weeks of treatment

Trial Profile

A double-blind, randomized, 2-way cross-over, phase II, efficacy trial in cancer patients to assess the overall efficacy, patient preference, morphine related side effect profile and safety of the Egalet controlled release morphine formulation 30-240 mg once daily compared to MST Continus [morphine sulphate] 15-120 mg twice daily after 2 weeks of treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Morphine (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Sponsors Egalet
  • Most Recent Events

    • 02 Jun 2009 Status changed from recruiting to completed.
    • 09 May 2009 Primary endpoint results presented at the 28th Annual Scientific Meeting of the American Pain Society
    • 09 May 2009 Status change from recruiting to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top